Ligand to receive $2 million from WuXi Biologics for licensing clinical-stage anti-PD-1
Ligand announces it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and other territories. Ligand is also entitled to future milestones and royalties. August 18, 2017